Business Wire

Zeitview Acquires Heliolytics, Becoming the Market Leader in Solar Aerial Inspections

6.9.2023 13:00:00 EEST | Business Wire | Press release

Share

Zeitview today takes the lead in advanced aerial inspections for energy and infrastructure by acquiring Heliolytics, which specializes in photovoltaic (PV) system performance via aerial inspection and integrated analytics. The acquisition of this former division of NovaSource Power Services enables the combining of Heliolytics' data insights with Zeitview’s expertise in aerial inspection technologies. The majority of Heliolytics staff will join Zeitview, and the team’s presence in Toronto, Canada, will continue. The amount of the deal was not disclosed.

"Heliolytics are pioneers in the solar industry and have earned a commendable reputation for their unwavering commitment to quality, precision, and exceptional customer service—values we hold in the highest esteem,” said Dan Burton, founder and Chief Executive Officer at Zeitview. “Their expertise and dedication are valuable as we continue developing groundbreaking solutions that redefine inspection standards within the renewable energy sector. We are excited for this next chapter in our journey, where our united teams create a complete market-winning solution."

For renewable energy customers, this collaboration reinforces Zeitview's multi-asset approach to solar, wind, and utilities. For property owners, it offers critical insights into the performance of their rooftop solar facilities. For all customers, Heliolytics' international operations in Europe, Latin America, and the Asian Pacific are also being combined with Zeitview's global footprint in those same regions.

“Joining forces with Zeitview is a tremendous opportunity to further the renewable energy industry,” said Jocelyne Moyer, Head of Heliolytics. Post-acquisition, Moyer takes the title of Senior Director of Strategy and Operations at Zeitview. “We have a shared commitment with Zeitview to deep client partnerships, science-driven innovation, and unparalleled responsiveness to our global clients. I am excited to join the leadership team and look forward to collaborations that will strengthen Zeitview’s role in the operations and maintenance of renewable energy assets.”

Heliolytics' inspection tools and integrated analytics are now supported by Zeitview's AI/ML data processing engine. With this addition, Zeitview doubles the reach and breadth of its airplane operations and adds topography, EPC, and drone solutions to Heliolytics, all of which can translate into faster, more comprehensive customer results.

With the sale of Heliolytics to Zeitview, NovaSource Power Services continues to offer best-in-class aerial inspection software and services to their customers via Zeitview.

“We are thrilled to continue our longstanding partnership with the Heliolytics team under the Zeitview name,” said Timo Moeller, Chief Growth Officer, NovaSource Power Services. “Zeitview’s impressive inspection and software tools will enhance the insights we currently use to support operations and maintenance requests. It is clear that the Zeitview team deeply understands our data needs and is committed to providing continued unrivaled expertise as aerial inspection providers to support our growth.”

A complete integration of Heliolytics operations, data capture, and software into Zeitview’s market-leading global solar solution is expected to be finished by the end of 2024.

To learn more about how Zeitview supports global energy and infrastructure through advanced inspections and actionable data, visit www.zeitview.com.

ABOUT ZEITVIEW

As a single partner for aerial inspections across a broad spectrum of industries, including solar, wind, real estate, telecom, and utility assets, Zeitview is trusted by the largest enterprises worldwide to deliver fast, accurate insights that optimize asset performance and reduce operating and maintenance costs. Combining state-of-the-art aerial inspection software with the ability to capture in-depth visual data via airplanes and drones, Zeitview harnesses the power of artificial intelligence and machine learning. Such aerial intelligence delivers customers actionable insights in near real-time and empowers organizations to make better-informed decisions about their most critical assets at scale.

Learn more about Zeitview's cutting-edge solutions at www.zeitview.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technica Communications for Zeitview
Cait Caviness
zeitview@technica.inc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye